---
title: "KERYX BIOPHARMA UK LTD. — Ownership Dossier"
canonical: https://whiteintel.dev/entity/29615c53-2800-534b-bd77-1d98c3e2a47a
json: https://whiteintel.dev/api/public/dossier/29615c53-2800-534b-bd77-1d98c3e2a47a
identifier: oo:GB-COH-08829670
jurisdiction: GB
risk: Low
source: WhiteIntel corporate-ownership graph
---

# KERYX BIOPHARMA UK LTD.

**Type:** Company  
**Jurisdiction:** [GB](https://whiteintel.dev/jurisdictions/gb)  
**Identifier:** `oo:GB-COH-08829670`  
**Risk level:** Low  
**Canonical dossier:** https://whiteintel.dev/entity/29615c53-2800-534b-bd77-1d98c3e2a47a  
**Structured JSON / MCP:** https://whiteintel.dev/api/public/dossier/29615c53-2800-534b-bd77-1d98c3e2a47a  

## Ownership & control

### Owners / controllers

- **US REAL ESTATE HOLDINGS NO. 4 LIMITED** (beneficial owner) — 100% — https://whiteintel.dev/entity/50fdc6a1-20dd-5bc7-850c-166ddc6db6dd
- **Akebia Therapeutics, Inc.** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/21584775-084d-4b62-a479-adba4c48a280
- **Keryx Biopharmaceuticals, Inc.** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/0940f7ec-dbe9-4223-870d-4d9022342592

### UBO chain (walk to the ultimate owner)

A **15-step** ownership/control chain to the ultimate beneficial owner is resolved for this entity. The full cited chain unlocks with a paid API key or a one-off dossier — https://whiteintel.dev/pricing.

## Company profile (live · UK Companies House)

- **Company number:** `08829670`
- **Status:** active
- **Type:** ltd
- **Incorporated:** 2014-01-02
- **Registered office:** Riverbank House, 2 Swan Lane, London, EC4R 3TT
- **SIC:** 74909

### Officers

- RUCCI, Carolyn Malvern — secretary · appointed 2024-08-06
- BUTLER, John Patrick — director · American · appointed 2019-02-05
- HADAS, Nicole Rosenkrantz — secretary · appointed 2019-02-05 · resigned 2024-08-06
- ADAMS, Brian — director · American · appointed 2015-04-30 · resigned 2018-05-09
- BENTSUR, Ron — director · American · appointed 2014-01-02 · resigned 2015-04-30
- HOLMES, Scott — director · American · appointed 2018-05-09 · resigned 2019-02-05
- MADISON, Gregory Paul — director · American · appointed 2015-04-30 · resigned 2018-05-09

### Beneficial owners (Persons with Significant Control)

- [Akebia Therapeutics, Inc.](https://whiteintel.dev/entity/21584775-084d-4b62-a479-adba4c48a280) — 75–100% shares · corporate PSC · United States — since 2018-12-12
- [Keryx Biopharmaceuticals, Inc.](https://whiteintel.dev/entity/0940f7ec-dbe9-4223-870d-4d9022342592) — 75–100% shares · corporate PSC · United States — ceased 2018-12-12

## Provenance

- OpenOwnership — https://find-and-update.company-information.service.gov.uk/company/08829670
- companies_house_bulk — https://find-and-update.company-information.service.gov.uk/company/08829670

## Get the full, resolved dossier (agent-callable)

The above is the free teaser. The resolved **multi-hop UBO chain**, ownership **%**, full **financial history**, itemised **assets** and the hop-by-hop **exposure path** are the paid depth — callable as tools from your agent:

```bash
npx -y @whiteintel/mcp-server   # then: get_dossier · trace_ownership_path · check_offshore_exposure
```

Or unlock a one-off cited dossier for **KERYX BIOPHARMA UK LTD.** — https://whiteintel.dev/entity/29615c53-2800-534b-bd77-1d98c3e2a47a · pricing https://whiteintel.dev/pricing.

---

_This is the markdown-for-agents view of the WhiteIntel dossier for **KERYX BIOPHARMA UK LTD.**. Human view: https://whiteintel.dev/entity/29615c53-2800-534b-bd77-1d98c3e2a47a · Structured JSON: https://whiteintel.dev/api/public/dossier/29615c53-2800-534b-bd77-1d98c3e2a47a._

_Risk levels are heuristic investigative leads, not legal determinations of beneficial ownership. Every claim carries a source; an absent edge means "not yet observed in current sources", not "does not exist"._